ERBB2 and gastric cancer: This pivotal phase 2 study was an open label, randomized study in Japan and South Korea that compared trastuzumab deruxtecan with the physician’s choice of chemotherapy in patients with HER2-positive gastric cancer who progressed after two or more previous therapies involving trastuzumab.